Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.8652W HIGH $6.61
Volume
202.58 K
Value Traded
718.09 K
Short % Float
2.29%
-1.66%Week
-6.03%1 Month
-30.02%3 Month
-31.8%6 Month
-1.44%5 Year
+404.62%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
135.96 M
EPS (TTM)
-0.04
P/E Ratio
-
Ent. Value
127.67 M
Total Shares
45.92 M
Float Shares
43.05 M
Insiders
6.76%
Institutions
55.62%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
KRMD Catalyst Timeline
Dated clinical, regulatory and corporate events for KORU Medical Systems, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for KORU Medical Systems, Inc.
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 3
Past FDA Catalysts and PDUFA Decisions
How KRMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
KORU Medical Systems, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every KRMD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KALBERMATTEN ADAM ROfficer (Chief Commercial Officer) | Buy | 32,000 394,017 held | $3.16 | 09/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KRMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.5 % (-37.5 %) | 3.10 M | 899.06 K | 5.6% ( 47.69 K) |
KRMD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KRMD ranks across every disease it competes in
Competitive Position is a premium feature
See how KRMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKRMD News
KRMD▼ -13.8%on this news
KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
KORU Medical Systems reported an 18% increase in net revenues for the second quarter of 2026. The company also provided an updated guidance for the full year, indicating a positive outlook for its financial performance. This growth reflects KORU's commitment to developing innovative subcutaneous infusion solutions.
Read more →KRMDKORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference
KORU Medical Systems, Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12th, 2026. This event highlights the company's commitment to innovation in large volume subcutaneous infusion solutions. Management's presentation is expected to provide insights into the company's strategic direction and growth potential.
Read more →KRMDKORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026
KORU Medical Systems, Inc. has announced that it will report its second quarter 2026 financial results on August 5, 2026. The company, known for its innovative large volume subcutaneous infusion solutions, will also host a conference call and webcast at 4:30 p.m. ET to discuss the results.
Read more →KRMDKORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress
KORU Medical Systems presented real-world data on the FreedomEDGE Syringe Infusion System at the 51st Annual Oncology Nursing Society Congress. The presentation focused on the system's benefits in infusion clinics. However, specific details about the data or outcomes were not provided in the article.
Read more →KRMDKORU Medical Systems Announces First Quarter 2026 Results
KORU Medical Systems has announced its financial results for the first quarter of 2026. The report includes key metrics and insights into the company's performance during this period. However, specific details regarding revenue, expenses, or other financial indicators were not provided in the article.
Read more →KRMDKORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026
KORU Medical Systems, Inc. will report its first quarter 2026 financial results on May 6, 2026. A conference call and webcast will be held at 4:30 p.m. ET to discuss these results and provide a corporate update. The company specializes in large volume subcutaneous infusion solutions aimed at improving patient quality of life.
Read more →KRMDKORU Medical Systems Announces CEO Transition
KORU Medical Systems announced the retirement of CEO Linda Tharby, effective June 30, 2026, after five years of leadership. Adam Kalbermatten, currently Chief Commercial Officer, will succeed her as CEO on July 1, 2026. The transition reflects the Board's confidence in Kalbermatten's capabilities and the company's strategic direction. Tharby will remain on the Board to support the transition.
Read more →KRMDKORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
KORU Medical Systems reported a 23.3% increase in Q4 2025 revenues, reaching $10.9 million, driven by strong demand for immunoglobulin therapy. The company also achieved a positive adjusted EBITDA of $0.5 million. For the full year, total revenues rose by 22.2% to $41.1 million, with significant international growth. KORU Medical has initiated guidance for 2026, reflecting optimism about future performance.
Read more →KRMDKORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
KORU Medical Systems has announced that its Freedom60 Infusion Pump has received EU MDR certification, allowing for commercialization in the European Union. This certification includes compatibility with 50 mL prefilled syringes, enhancing the delivery of subcutaneous immunoglobulin therapy. The FreedomEDGE Infusion System also supports 20 mL prefilled syringes, providing flexibility for patients and clinicians.
Read more →KRMDKORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
KORU Medical Systems, Inc. will report its fourth quarter and full year 2025 financial results on March 12, 2026. A conference call and webcast will follow at 4:30 p.m. ET for management to discuss the results and provide a corporate update. The company specializes in large volume subcutaneous infusion solutions.
Read more →KRMDKORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System
KORU Medical Systems has received FDA 510(k) clearance for its FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli). This approval allows healthcare professionals to administer the therapy, enhancing access for patients with generalized myasthenia gravis. The clearance marks a significant expansion of KORU's infusion system capabilities, further establishing its position in the large-volume subcutaneous infusion market.
Read more →KRMDKORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow
KORU Medical Systems reported preliminary unaudited results for Q4 and the full year 2025, highlighting a significant increase in revenue. The company expects Q4 net revenues to be $10.9 million, a 23% increase year-over-year, and full year revenues of $41.1 million, growing by 22%. Positive operating cash flow has been achieved, with an ending cash balance of $8.9 million. KORU's CEO noted the strong performance and momentum heading into 2026, fueled by the company's strategic expansion and product advancements.
Read more →KRMDKORU MEDICAL SYSTEMS ANNOUNCES 27% Q3 REVENUE GROWTH AND RAISES 2025 REVENUE GUIDANCE
Koru Medical Systems reported a substantial revenue growth of 27% for Q3 2025, reaching $10.4 million. The core business segment experienced a 30% increase, propelled by new collaborations in pharmaceutical services and clinical trials. Despite the positive financial growth, the company still faced a net loss of $0.8 million and a decline in domestic core revenues. Additionally, the gross margin has decreased due to rising costs and tariffs, although the company remains optimistic about revenue growth and cash flow improvements for the full year.
Read more →KRMDKORU MEDICAL SYSTEMS ANNOUNCES Q2 2025 FINANCIAL RESULTS, INCLUDING RECORD DOUBLE-DIGIT REVENUE, AND RAISES 2025 REVENUE GUIDANCE
Koru Medical Systems reported a strong financial performance for Q2 2025, achieving a 21% year-over-year increase in net revenues, totaling $10.2 million. The company also raised its revenue guidance for the full year 2025, anticipating revenues between $39.5 and $40.5 million. Despite a slight decrease in gross margin, Koru Medical celebrated the milestone of surpassing $10 million in revenue for the first time and continues to enhance its offerings with new managerial hires and FDA submissions for its infusion systems. The firm plans to discuss these results in an upcoming conference call.
Read more →KRMDKORU MEDICAL SYSTEMS ANNOUNCES RECORD Q1 2025 FINANCIAL RESULTS AND RAISES 2025 REVENUE GUIDANCE
Koru Medical Systems announced a strong performance in Q1 2025, with net revenues reaching $9.6 million, an increase of 18% from the previous year. The company raised its full-year revenue guidance to between $38.5 million and $39.5 million based on robust growth in its core business. However, despite these positive results, the company noted a significant drop in revenue from pharma services and clinical trials and continued to operate at a loss, albeit decreasing from prior periods. Koru Medical also plans to submit two drug applications for FDA clearance in 2025.
Read more →KRMD▲ +5.5%on this news
KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results with Record Revenues and Gross Profit; Issues Full Year 2025 Guidance
KORU Medical Systems reported impressive financial results for the fourth quarter and full year of 2024, highlighting record revenues and gross profits. The company experienced substantial growth in both its core and novel therapies segments, with a notable 122% increase in novel therapies revenue for Q4. Additionally, KORU Medical announced positive cash flow for Q4 and a significant reduction in full-year cash burn. Looking ahead, the company issued optimistic guidance for 2025, expecting revenues to increase by 13% to 16%. The novel therapies segment will be rebranded to better reflect its revenue model.
Read more →KRMDKORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter MAHWAH, NJ
KORU Medical Systems has reported preliminary fourth quarter and full year 2024 results, showcasing impressive financial growth. The company anticipates fourth quarter net revenues of $8.9 million, a 23% increase from the previous year, and full year revenues of $33.7 million, up 18%. Notably, KORU also achieved a positive cash flow of $0.8 million for the fourth quarter and improved its cash burn by 67% over the prior year. KORU plans to release detailed financial results in March 2025, with expectations of further growth as it expands its market share and product offerings.
Read more →KRMD▲ +7.7%on this news
KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 Q3 FINANCIAL RESULTS, THIRD CONSECUTIVE QUARTER OF DOUBLE-DIGIT GROWTH; RAISES FULL YEAR 2024
Koru Medical Systems, Inc. (KRMD) reported its financial results for Q3 2024, highlighting a 17% increase in net revenues to $8.2 million and notable growth in novel therapies, which surged by 276%. This marks the company's third consecutive quarter of double-digit growth. In addition, Koru has raised its full-year revenue guidance to between $32.75 million and $33.25 million, alongside improved gross margin projections. While the company is expanding its patient base and maintaining a healthy cash position, it still recorded a net loss of $1.6 million.
Read more →KRMDKORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 Q2 FINANCIAL RESULTS, A RECORD QUARTER WITH 22% REVENUE GROWTH; RAISES FULL YEAR 2024
Koru Medical Systems, Inc. reported a strong second quarter for 2024, achieving net revenues of $8.4 million, marking a 22% increase from the previous year. The company raised its revenue and gross margin guidance for the full year, reflecting confidence in its continued growth. Key drivers included significant gains in both the domestic and international markets, as well as advancements in their novel therapies pipeline. Overall, the company demonstrated improved financial performance and operational efficiencies.
Read more →About KORU Medical Systems, Inc.
Headquarters100 CORPORATE DRIVE, MAHWAH, NJ, 07430
BIOPHARMAWATCH ELITE PLUS
Trade the next KRMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime